Investment vehicles tied to RA Capital Management, L.P. have increased their exposure to Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) through a series of purchases in late June. According to a filing submitted to the Securities and Exchange Commission, the total value of these acquisitions amounted to approximately $292,126. The transactions were carried out by RA Capital Healthcare Fund, L.P. on June 25 and June 26, 2026. This reported activity highlights ongoing institutional interest in the biotech company, even as the stock has seen dramatic price appreciation over the last twelve months.
The timing of these purchases is notable given ARTV's recent market performance. Over the past year, the stock has surged by 554%, reaching a current trading price of $9.61. This price level corresponds to a market capitalization of $467 million. Despite this significant run-up, analyst sentiment remains positive, with price targets established between $23 and $41 per share. However, an analysis from InvestingPro indicates that the stock's current valuation may exceed its fair value estimate. On the other hand, the company's financial position appears robust, with a balance sheet that holds more cash than debt and a strong current ratio of 8.16.
The specific details of the June transactions reveal a pattern of accumulation at varying price points. On June 25, RA Capital Healthcare Fund, L.P. acquired 31,000 shares of ARTV common stock. These shares were purchased at a weighted average price of $8.88 per share, with individual transactions occurring at prices ranging from $8.62 to $8.98. The following day, June 26, the fund purchased an additional 1,876 shares at a weighted average price of $8.98 per share. These subsequent transactions were executed at prices between $8.97 and $9.00. The combined weighted average price for all transactions by RA Capital Healthcare Fund, L.P. ranged from $8.88 to $8.98.
Following these recent acquisitions, RA Capital Healthcare Fund, L.P. now holds a total of 16,795,919 shares of Artiva Biotherapeutics common stock. RA Capital Management, L.P. acts as the investment manager for this fund, as well as for RA Capital Nexus Fund, L.P., RA Capital Nexus III Fund, L.P., and a separately managed account. Peter Kolchinsky and Rajeev Shah serve as managing members of RA Capital Management GP, LLC, which is the general partner of RA Capital Management, L.P. The individuals reporting these transactions have disclaimed beneficial ownership of the securities, except to the extent of their pecuniary interest.
Beyond the primary fund, other affiliated entities maintain indirect holdings in the company. RA Capital Nexus Fund, L.P. holds 264,571 shares, while RA Capital Nexus Fund III, L.P. holds 826,832 shares. Additionally, a separately managed account holds 68,320 shares. Laura Stoppel, who serves as a Principal of RA Capital Management, L.P., also sits on the board of directors for Artiva Biotherapeutics, providing a direct governance link between the investment manager and the company.
Recent corporate developments at Artiva Biotherapeutics include significant regulatory and clinical milestones. The company announced that its rheumatoid arthritis treatment, AlloNK in combination with rituximab, has received Regenerative Medicine Advanced Therapy designation from the Food and Drug Administration. This designation is designed to facilitate expedited development and review processes, potentially speeding the treatment's path to market. Furthermore, the company presented clinical data at the European Alliance of Associations for Rheumatology Congress, reporting that 71% of patients in a Phase 2a trial achieved significant disease improvement after six months of treatment.
Market reaction to these developments has been reflected in analyst coverage. Cantor Fitzgerald has maintained an Overweight rating on Artiva Biotherapeutics, keeping its price target at $40.00. The firm highlighted the company's strategic focus and manufacturing capabilities as key strengths. On the organizational front, Artiva has appointed Diego Miralles, M.D. as President and Head of Research and Development. This appointment follows his resignation from the company's board of directors, signaling a shift in leadership structure as the company advances its therapeutic pipeline.